← Search & browse all drugs

ioxaglic acid

V08AB03

Forms & Strengths

Injectable solution: 32% ioxaglate meglumine and ioxaglate sodium (equivalent to 320 mg/mL iodine)
Injectable solution: 39% ioxaglate meglumine and ioxaglate sodium (equivalent to 393 mg/mL iodine)

Adult Dosing

Intravenous digital subtraction angiography: 30 to 50 mL per injection
Peripheral angiography: 20 to 100 mL per injection
Cerebral angiography: 5 to 12 mL per injection
Coronary angiography and ventriculography: 30 to 50 mL per injection
Excretory urography: 40 to 100 mL single dose

Pediatric Dosing

Safety and efficacy in pediatric patients have not been established
Use in children is generally avoided unless potential benefits outweigh risks

Indications

Diagnostic contrast agent for angiocardiography
Coronary arteriography and left ventriculography
Peripheral and cerebral arteriography
Excretory urography

Mechanism of Action

Low-osmolar, ionic, monoacid dimeric radiocontrast agent
Contains organically bound iodine that absorbs X-rays, opacifying blood vessels and urinary tract structures

Contraindications

Known hypersensitivity to ioxaglic acid or iodinated contrast media
Manifest hyperthyroidism
Intrathecal administration is strictly contraindicated due to severe neurotoxicity

Adverse Reactions

Mild to moderate transient warmth, flushing, or pain at injection site
Nausea, vomiting, headache, and dizziness
Hypersensitivity reactions ranging from mild urticaria to severe anaphylaxis
Contrast-induced nephropathy
Arrhythmias and hypotension during angiocardiography

Drug Interactions

Metformin: Risk of lactic acidosis; discontinue metformin at time of or prior to procedure and withhold for 48 hours post-procedure
Beta-blockers: May exacerbate severe hypersensitivity reactions and reduce responsiveness to treatment with epinephrine
Interleukin-2: Increased risk of delayed hypersensitivity reactions (fever, rash, flu-like symptoms)

Curated Content: Needs Vetting Before Put to Clinical Use